Literature DB >> 28495473

Genetic polymorphisms of the P2X7 gene associated with susceptibility to and prognosis of pulmonary tuberculosis.

Xianzhi Zheng1, Tiecheng Li2, Yongzhong Chen3, Hongqiu Pan3, Zhihai Zhang4, Yaoyao Dai4, Jianming Wang5.   

Abstract

In this population-based case control study, we recruited 1601 pulmonary tuberculosis cases and 1526 healthy controls, aiming to investigate the association of genetic polymorphisms of the P2X7 gene with the susceptibility to and prognosis of pulmonary tuberculosis in a Chinese Han population. Five single-nucleotide polymorphisms (SNPs) in the P2X7 gene were genotyped. The odds ratio (OR) or relative risk (RR) together with 95% confidence interval (CI) were used to estimated the effect of genetic polymorphisms on the disease. After correction for multiple comparisons, the SNP rs1718119 remained significant. The allele A of rs1718119 was related to a reduced risk for all active tuberculosis (OR for each additional allele A: 0.81, 95% CI: 0.69-0.94) and sputum smear-positive cases (OR for each additional allele A: 0.78, 95% CI: 0.66-0.93). The effects of these genetic variations were more evident among smokers. Survival analysis showed a weak association between rs7958311 and treatment outcome, where each additional allele A of the SNP rs7958311 contributed to a 59% increase in the probability of a successful treatment outcome (adjusted RR: 1.59, 95% CI: 1.05-2.40, P=0.028); but it wasn't significant after the Bonferroni correction. We demonstrated that genetic variations of the P2X7 gene might be involved in the risk and prognosis of human tuberculosis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gene; P2X7; Polymorphism; Prognosis; Susceptibility; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28495473     DOI: 10.1016/j.meegid.2017.05.003

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  8 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  P2RX7 at the Host-Pathogen Interface of Infectious Diseases.

Authors:  Alexandra Y Soare; Tracey L Freeman; Alice K Min; Hagerah S Malik; Elizabeth O Osota; Talia H Swartz
Journal:  Microbiol Mol Biol Rev       Date:  2021-01-13       Impact factor: 11.056

Review 3.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Authors:  Geoffrey Burnstock; Gillian E Knight
Journal:  Purinergic Signal       Date:  2017-11-21       Impact factor: 3.765

Review 4.  The Research Progress of Host Genes and Tuberculosis Susceptibility.

Authors:  Li Cai; Zhan Li; Xuhua Guan; Kun Cai; Lei Wang; Jiafa Liu; Yeqing Tong
Journal:  Oxid Med Cell Longev       Date:  2019-08-14       Impact factor: 6.543

Review 5.  Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion.

Authors:  Hongmin Kim; Sung Jae Shin
Journal:  Front Cell Infect Microbiol       Date:  2022-07-28       Impact factor: 6.073

Review 6.  P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells.

Authors:  Valentina Vultaggio-Poma; Francesco Di Virgilio
Journal:  Biomolecules       Date:  2022-07-14

7.  Combining bioinformatics and biological detection to identify novel biomarkers for diagnosis and prognosis of pulmonary tuberculosis.

Authors:  Guanren Zhao; Xiaobo Luo; Xue Han; Zhen Liu
Journal:  Saudi Med J       Date:  2020-04       Impact factor: 1.484

8.  Association Between Functional Nucleotide Polymorphisms Up-regulating Transforming Growth Factor β1 Expression and Increased Tuberculosis Susceptibility.

Authors:  Su Zhang; Guobao Li; Jing Bi; Qinglong Guo; Xiangdong Fu; Wenfei Wang; Shuyan Liu; Guohui Xiao; Min Ou; Juanjuan Zhang; Xing He; Fang Li; Guanqiang Li; Carl G Feng; Xinchun Chen; Guoliang Zhang
Journal:  J Infect Dis       Date:  2022-03-02       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.